<DOC>
	<DOCNO>NCT00494507</DOCNO>
	<brief_summary>The purpose study compare Dichlorphenamide placebo ( inactive substance ) prevention episode improvement strength hyperkalemic ( HYP ) hypokalemic ( HOP ) periodic paralysis . This study also look long-term effect Dichlorphenamide periodic paralysis .</brief_summary>
	<brief_title>Hyper- Hypokalemic Periodic Paralysis Study</brief_title>
	<detailed_description>Periodic paralysis relatively rare , life-long disorder characterize intermittent bout paralysis , progressive weakness , diminish quality life . Two drug , acetazolamide ( ACZ ) dichlorphenamide , prescribe treat disorder , however , dichlorphenamide longer available . In multi-center , parallel , randomize trial researcher compare effect dichlorphenamide vs. placebo patient hyperkalemic ( HYP ) hypokalemic ( HOP ) periodic paralysis . The trial consist two 9-week studiesâ€”one study enroll person hyperkalemic periodic paralysis study enroll person hypokalemic periodic paralysis . Participants randomly assign one two treatment group : dichlorphenamide placebo ( inactive substance ) . During study , participant ask keep daily diary record time , length , severity episode weakness ( attack ) . The study coordinator contact participant weekly review diary information . The 9-week phase follow 1-year open-label dichlorphenamide extension without placebo determine long-term effect dichlorphenamide course disease inter-attack weakness . Duration trial participant approximately 65 week , include screen phase determine eligibility , first 9-week treatment phase , one-year open-label extension phase .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Hypokalemic Periodic Paralysis</mesh_term>
	<mesh_term>Paralysis , Hyperkalemic Periodic</mesh_term>
	<mesh_term>Dichlorphenamide</mesh_term>
	<criteria>Genetically definite , clinically definite clinically probable Hyperkalemic Hypokalemic Periodic Paralysis outline protocol Male female participant , age 18 old able comply study condition . Participants distinct regular episode weakness average frequency &gt; = 1 week &lt; = 3 day either treatment , whichever high Normal thyroidstimulating hormone ( TSH ) level Evidence AndersenTawil syndrome ( one follow 3 criterion ) 1 . Prolonged QT interval complex ventricular ectopy attack 2 . Distinctive physical feature ( 2 follow 5 ) 1 . Low set ears 2 . Short stature 3 . Hypo/micrognathia 4 . Clinodactyly 5 . Hypo/hypertelorism 3 . KIR 2.1 gene mutation Coincidental renal , hepatic , active thyroid disease , restrictive obstructive lung disease , neuromuscular disease , heart disease Chronic , noncongestive , angleclosure glaucoma Use follow medication reason treatment periodic paralysis : diuretic , antiarrhythmic , corticosteroid , betablockers , calcium channel blocker , antiepileptic , magnesium History lifethreatening episode respiratory muscle weakness cardiac arrhythmia attack Pregnancy Known mutation alpha subunit sodium channel gene hypokalemic periodic paralysis patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>periodic paralysis</keyword>
	<keyword>dichlorphenamide</keyword>
</DOC>